SOUTH SAN FRANCISCO, Calif., June 13, 2021 (GLOBE NEWSWIRE) – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunological biopharmaceutical company focused on the discovery, development and commercialization of small molecule oral therapies for patients with Significant unmet needs in oncology and inflammatory diseases today announced that the company plans to report first-line data from its Phase 1b clinical trial of RPT193 in patients with moderate to severe atopic dermatitis (AD) in a pre-market press release and webcast on Monday, June 14, 2021.
RAPT will host a conference call accompanied by a slideshow at 8:30 am EDT on Monday, June 14th. The live webcast and audio file of the presentation can be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. The conference call can be accessed by dialing (833) 672-0665 (national) or (929) 517-0344 (international) and referring to conference ID 4696044. The webcast will be available for replay for 30 days. Log in to the site 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be needed to listen to the webcast.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on the discovery, development and commercialization of small molecule oral therapies for patients with significant unmet needs in oncology and inflammatory diseases. Using its proprietary discovery and development mechanism, the company is developing highly selective small molecules designed to modulate the essential immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting the C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The company is also pursuing a number of targets that are in the discovery stage of development.
RAPT Media Contact:
RAPT investor contact: